Objective: Dietary supplementation with guar gum or fructose has been reported to reduce the postprandial glycemic response to an oral glucose challenge. As a result of the poor palatability of most foods containing guar gum, a novel low-viscosity beverage with guar gum was developed that becomes viscous in vivo through an enzymatic induction. The primary study objective was to determine the effect of an amylase-induced viscosity (I-V) product, with or without supplemental fructose, on the postprandial glycemic response to a high glycemic index test meal in healthy nondiabetic subjects. Design: The study was a four-treatment, placebo-controlled, double-blind, randomized block protocol. Setting: The study was performed at Glycaemic Index Testing, Inc., Toronto, Ontario, Canada. Subjects: A total of 30 healthy nondiabetic volunteers (13 male, 17 female, mean7s.e.m. age of 5173 y and body mass index of 24.270.4 kg/m 2 ) participated in the study. Intervention: In the morning after an overnight fast, subjects participated in four 3-h meal glucose tolerance tests on separate occasions. The test meals contained 50 g of available carbohydrate from maltodextrin and white bread (control) or the same meal with either 5 g of guar gum (3.6 g galactomannan), 5 g of fructose, or 5 g of guar gum þ 5 g of fructose.
Introduction
Purified viscous forms of dietary fiber have potential benefits for improving postprandial glycemia (Jenkins et al, 1978; Anderson et al, 1987; Wolever & Jenkins, 1993) . Although high viscosity appears to be a necessary property of fiber to maximize its benefits on blood glucose (Jenkins et al, 1978) , high viscosity reduces the palatability of foods (Ellis et al, 1991) , which is a major impediment to the practical use of viscous fiber. Recently, low dextrose equivalent (DE) maltodextrins were reported to prevent the dissolution of konjac flour (glucomannan) (Crosby, 2000) , which should improve palatability. We have found that certain protein sources or low DE maltodextrins can prevent the dissolution of neutral polymers like guar gum (galactomannan; unpublished information). A product formulated with the proper type of fiber and an appropriate starch source could have low viscosity in the absence of a-amylase but, upon ingestion, salivary amylase would hydrolyze the maltodextrin, allowing the fiber to solubilize and form a viscous chyme. This novel concept will be referred to as amylase-inducedviscosity (I-V). We hypothesized that the amylase I-V system would attenuate postprandial glycemia.
Fructose has a low glycemic index (Crapo et al, 1980; Jenkins et al, 1981) . In Zucker fatty fa/fa rats (a model of insulin resistance), Wolf et al (2002) found that fructose addition (0.16 g/kg body wt) to an oral glucose challenge (1.0 g/kg body wt) reduced (Po0.05) the incremental area under the curve (AUC) for plasma glucose by 34% over the 3-h experiment. In addition, they demonstrated that supplemental fructose attenuates the postprandial glycemic response to a rapidly digested starch (ie maltodextrin). We hypothesized that small amounts of oral fructose may be useful in lowering the postprandial glucose response to a carbohydrate (maltodextrin) challenge. Furthermore, we hypothesized that there may be a synergistic effect of amylase I-V and fructose.
Before the recommendation of a product concept, physiological efficacy must be demonstrated. The objective of this experiment was to evaluate the effects of an amylase I-V system and/or fructose on postprandial glycemic and breath hydrogen responses, gastrointestinal tolerance, and satiety in healthy nondiabetic individuals.
Methods
In vitro evaluation of viscosity To demonstrate the enzymatically I-V dietary fiber, an in vitro experiment was conducted. In total, 10% (wt/wt) hydrolyzed starch solutions were made with DE 1 maltodextrin (Star D, A.E. Staley Manufacturing Co., Decatur, IL, USA) or DE 20 corn syrup solids (Maltrin s M200, Grain Processing Corporation, Muscatine, IA, USA) and 701C water. Guar gum (2 g/100 g) was added to these solutions. Solutions were allowed to cool to room temperature before analysis. Change in viscosity was measured after adding 10 ml of heat-stable aamylase (EC 3.2.1.1, Sigma, St Louis, MO, USA) to 35 g of product. Viscosity was measured using a Rapid Visco Analyzer (Newport Scientific, Australia) at 371C and 200 rpm. (Wolever et al, 1991; Philipson et al, 1992) . The inclusion of these carbohydrate sources enabled the evaluation of the exploratory concepts during an MGTT. For the beverages, ingredients were made into a solution with water, filled into 250-ml metal cans, and terminally sterilized (Ross Products Division of Abbott Laboratories, Columbus, OH, USA). White bread was made as described by Wolever and Bolognesi (1996) . A 50-g available carbohydrate load for an MGTT is a standard practice (Jenkins et al, 1981; Wolever et al, 1991) . A 5-g guar gum (3.6 g galactomannan) level was chosen because it was at the upper limit of addition to the 240-g test formula (approximately 2% solution) and is a level known to be effective in lowering the postprandial glycemic response when incorporated into a snack bar (Ebeling et al, 1988) . In addition, Wolever and Jenkins (1993) document that guar gum levels as low as 2.5 g are effective in reducing postprandial blood glucose and insulin concentrations. A 5-g fructose level was chosen because this dose (approximately 0.075 g/kg body weight) has been shown to blunt effectively the postprandial glycemic response to a rapidly digested starch in Zucker fatty fa/fa rats . In addition, 5 g of fructose is at an appropriate level to sweeten the product.
Subjects

Experimental design
The study was a four-treatment, placebo-controlled, doubleblind, randomized block design in which subjects participated in four 3-h MGTT on separate occasions. Subjects were randomly assigned to one of 24 treatment sequences. After an overnight fast, subjects consumed the appropriate test meal. To ensure that subjects had similar glycogen stores on the four test days, subjects were instructed to consume a high-carbohydrate diet (goal 300 g/day, minimum 150 g/day) for 3 days before each MGTT and also were asked to avoid exercise for 24 h before the experiment. On the evening before each MGTT, all subjects consumed a low-residue dinner consisting of one 237-ml can of chocolate Ensure Plus s with additional Honey Graham Crunch Ensure s Bars to provide one-third of each subject's individual daily caloric requirement as estimated by the Harris-Benedict equation multiplied by an activity factor of 1.3 (Harris and Benedict, 1919) . After their low-residue evening meal, subjects were instructed to fast overnight, during which period they were allowed to consume only water. Smoking was prohibited. Subjects returned on average within 9 days for repeat analysis with the appropriate crossover treatment. Subjects were allowed water (250 ml) during each 3-h test. All subjects were recruited and enrolled from one study site.
Blood glucose analysis
A fasting (mean of 13 h, range 10-15 h) finger-prick capillary blood sample was obtained and collected into a fluorooxalate tube after 30 min of rest. Subjects then consumed the appropriate test meal within 10 min. Finger-prick capillary blood was obtained at 15, 30, 45, 60, 90, 120 , and 180 min postprandial. Samples were stored at -201C for a maximum of 3 days until the analysis of whole blood glucose. Capillary blood glucose was measured by the glucose oxidase method using a YSI analyzer (model YSI 2300 STAT PLUS, Yellow Springs Instruments, Yellow Springs, OH, USA).
Gastrointestinal tolerance
Using a questionnaire, subjects were asked to report the frequency and intensity of symptoms of nausea, cramping, distention, and flatulence for the 24-h period immediately following the consumption of the test material. Intensity and frequency were set to a 100-mm line scale (0 representing 'absent' and 100 'severe' and 0 representing 'usual' and 100 'more than usual', respectively). Subjects placed a single perpendicular slash mark across the 100-mm horizontal line to indicate their scores for each of these variables of frequency and intensity. A score of 5 or less was considered to be not physiologically meaningful. As such, gastrointestinal tolerance data were classified as 'no' (0-5) or 'yes' (45-100).
Satiety
In order to assess the subjective feeling of hunger, subjects completed a satiety questionnaire immediately before the MGTT, at 1, 2, and 3 h postprandial, and immediately before and after their lunch meal that followed the MGTT. Subjects rated their feeling of hunger with the following scale: 1 ¼ not at all hungry; 3 ¼ slightly hungry; 5 ¼ moderately hungry; 7 ¼ very hungry; 9 ¼ extremely hungry. In addition, subjects reported the amount of lunch consumed as: much less than 
usual, moderately less than usual, somewhat less than usual, slightly less than usual, about the same, slightly more than usual, somewhat more than usual, moderately more than usual, or much more than usual.
Breath hydrogen and methane A subset of 10 subjects was evaluated for carbohydrate malabsorption by measuring their end-alveolar hydrogen and methane concentrations hourly for 8 h after they ingested their MGTT. Samples of end-alveolar air were collected into 10-ml glass vacuum tubes using an EasySampler s device (Quintron Instruments, Milwaukee, WI, USA). At 5-h postprandial, subjects were given a standard lunch consisting of one or two 237-ml cans of chocolate Ensure Plus (the number of cans remained consistent for each subject). After the initial 3-h MGTT, these subjects were allowed free access to water.
The concentrations of carbon dioxide, hydrogen, and methane in breath samples were analyzed by gas chromatography (Microlyzer Gas Analyzer, model SC; Quintron Instruments). The observed hydrogen and methane values were corrected for atmospheric contamination of alveolar air by normalizing the concentrations of observed carbon dioxide to 5.26% (5.33 kPa, or 40 Torr, the partial pressure of carbon dioxide in alveolar air) (Holum, 1982) . Changes in hydrogen concentrations were calculated by subtracting the lowest hydrogen concentration among the 0, 1, or 2 h samples from the subsequent values. Rather than consistently using the time 0 value, the nadir value was selected as the baseline because some subjects have residual hydrogen accumulation in the colon during sleep that may be excreted over the first few hours of the experiment; thus the time 0 value may not reflect a true basal breath hydrogen level (Read et al, 1985; Hertzler et al, 1996) . Subjects were classified as having carbohydrate malabsorption (ie positive breath hydrogen test) if their breath hydrogen concentrations increased by more than 10 parts per million (0.9 Â 10 6 g hydrogen/l air or 0.45 mmol/l) from their basal nadir value (Strocchi et al, 1993) .
Study variables
The primary variable for this study was the incremental (ie baseline-adjusted) peak blood glucose response. Secondary variables for this study were the positive incremental AUC for blood glucose; the relative glycemic response; the mean incremental change from baseline in blood glucose at 15, 30, 45, 60, 90, 120 , and 180 min postprandial; a positive breath hydrogen test; and the subjective gastrointestinal tolerance and satiety factors.
Calculations
Positive incremental AUC for glucose was calculated according to Wolever et al (1991) . The areas after the challenge were calculated with the trapezoid rule, and areas below the baseline fasting blood glucose concentration were ignored. Relative glycemic response was calculated as (incremental AUC for treatment/incremental AUC for control) Â 100.
Statistical methods
If a subject had one or more glucose measurements missing between 0 and 180 min (both inclusive) during a visit, their data for that visit were not included in the analyses of peak incremental change from baseline in blood glucose and positive incremental AUC. These data were analyzed using a mixed model approach for crossover trials, with treatment and period effects as fixed, and subject effect as random. Incremental change from baseline in blood glucose at individual time points was analyzed using a mixed model approach for crossover trials, with treatment effect as fixed, and subject effect as random. Different covariance structures were tested according to Brown and Prescott (1999) . Compound symmetry variance pattern was found to be the most adequate. Residuals from these models were plotted against the predicted values in order to perform model checking. Treatments were arranged as a 2 Â 2 factorial by the presence or absence of amylase I-V and fructose. The amylase I-V Â fructose interaction was not significant; therefore, statistical results represent main effects of amylase I-V or fructose (SAS version 8.0, SAS Institute, Cary, NC, USA). For the classified gastrointestinal tolerance data, treatment differences were analyzed using sign tests with stepdown Bonferroni P-value adjustments. All results were considered to be statistically significant if the significance level was less than 0.05. P-values are reported as two-sided.
Results
The baseline viscosity of the 10% DE 20 corn syrup solids solution with 2% guar gum was very high and would not be compatible with liquid product manufacturing (see Table 2 ). However, a 2% guar gum solution in the presence of DE 1 maltodextrin (10 g/100 g) had a low baseline viscosity but had a sharp increase in viscosity after 10 min of in vitro digestion with a-amylase. For comparative purposes, we have shown that the viscosity of a 10% DE 1 maltodextrin solution is low compared with our I-V concept. In addition, without the addition of a-amylase, the viscosity of a 10% DE 1 maltodextrin solution with 2 g guar gum/100 g did not change over time. Clinical characteristics of subjects evaluated in this experiment are presented in Table 3 . The mean fasting blood glucose concentration was not different (P40.20) among treatments. Table 4 presents data for incremental peak glucose concentration, positive incremental AUC, and relative glycemic response. Peak incremental blood glucose concentration was lower (Po0.01) when subjects consumed either test meal containing amylase I-V compared with the other treatments, whereas the meal with only supplemental fructose increased (Po0.05) peak incremental blood glucose concentration. Incremental AUC was lower (Po0.01) when subjects consumed the amylase I-V containing products, and fructose had no effect (P40.05). The mean relative glycemic response (7s.e.m.) was 8075.8, 10874.2, and 9175.2 for amylase I-V, fructose, and I-V þ fructose, respectively.
The postprandial glycemic excursion is graphically depicted in Figure 1 . When subjects consumed test meals containing amylase I-V, the postprandial rise in blood glucose was reduced (Po0.05) at 15, 30, 45, and 60 min. In addition, there was a slower late postprandial decrease in blood glucose as shown by higher (Po0.05) blood glucose concentrations at 120 and 180 min, indicating slower and more prolonged carbohydrate absorption. Time to peak glucose concentration was delayed when subjects consumed products containing amylase I-V compared with the other treatments.
Up to four of 30 subjects reported a higher intensity and frequency of cramping, distension, or flatulence when they consumed the amylase I-V containing products (Table 5 ). However, no statistical differences (P40.05) were found among treatments. The frequency at which subjects tested positive for the breath hydrogen test was lower when subjects consumed fructose compared with the other treatments (60, 50, 20, and 70% for control, amylase I-V, fructose, and I-V þ fructose, respectively). In contrast to the subjective gastrointestinal tolerance data, the frequency of positive breath hydrogen tests was similar when subjects consumed the control and the amylase I-V containing products.
Two adverse events were reported following consumption of the guar gum-containing products (one following amylase I-V and one following I-V þ fructose). These adverse events Mean7s.e.m., n=30 except for I-V þ fructose, n=29. Baseline fasting blood glucose concentrations were 4.3770.09, 4.4870.12, 4.4670.08, and 4.4570.10 mmol/l for subjects consuming control, amylase-induced-viscosity (amylase I-V), fructose, and amylase-induced-viscosity þ fructose (I-V þ fructose), respectively. To convert glucose mmol/l to mg/dl, multiply mmol/ l by 18.01 (glucose of 5.0 mmol/l=90 mg/dl). AUC: area under the curve. b Effect of amylase I-V, Po0.01. were associated with gastrointestinal intolerance, diarrhea, and cramping and were transient in nature (self-resolved within 24 h). It was concluded that these adverse events were not of any safety concern. Certain individuals are more susceptible to gastrointestinal symptoms following a dose of fermentable fiber (in this case, guar gum). No serious adverse events occurred throughout the trial. Subjective ratings of hunger during the 3-h MGTT and immediately before and after the lunch meal were similar among treatment groups (data not shown). In addition, the estimated amount of food consumed during the lunch meal following the MGTT was similar among treatment groups.
Discussion
Numerous clinical studies have evaluated the acute and long-term effects of supplemental guar gum on glycemic control. Although a dose-response trial has not been completed, guar gum doses in the range of 1.8-15 g have been found to improve the postprandial glycemic response to oral glucose tolerance tests and MGTT in nondiabetic (Gatti et al, 1984; Jarjis et al, 1984; Heijnen et al, 1995) and diabetic (Gatti et al, 1984; Fuessl et al, 1986; Ebeling et al, 1988) subjects, although Williams et al (1980) reported no effect. In people with diabetes, medium-to long-term (range 4 weeks to 1 y) guar gum supplementation (9-60 g/day) also has shown metabolic improvements in blood glucose control (Aro et al, 1981; Gatti et al, 1984; Kirsten et al, 1992; Groop et al, 1993) . However, many studies have reported no effect on glycemic control (Cohen et al, 1980; Uusitupa et al, 1989; Wilson et al, 1989) ; the dose of guar gum or the method of guar gum preparation and timing of delivery may be the reason for the discrepancy between studies on glycemic control.
Our novel amylase I-V system allows the production of a palatable, liquid ready-to-feed, guar gum-containing product that innately allows an intimate mixing of the meal with guar gum, which is essential for its effect on carbohydrate metabolism Fuessl et al, 1986) . We speculate that a meal replacement formulated with the amylase I-V system will have superior clinical efficacy than if it was given as a premeal drink or dietary supplement (eg capsule). In fact, Wolever et al (1979) suggest that guar gum is most effective when added to the liquid phase of the meal because the guar gum is fully hydrated and thus at its highest viscosity, which is an important factor in its clinical efficacy (Jenkins et al, 1978; Ellis et al, 1986) . Furthermore, when consumed as a pill, guar gum has been associated with esophageal obstruction (Seidner et al, 1990) .
Foodstuffs containing guar gum usually exhibit slimy mouth-feel (Williams et al, 1980) , tooth packing (Tredger & Ransley, 1978) , and poor palatability (Ellis et al, 1991) . The overall hedonic quality of guar-containing foods can be improved by reducing the average molecular weight (ie through hydrolysis) of the galactomannan in guar gum (Ellis et al, 1991) ; however, this results in a concurrent loss in clinical efficacy (Jenkins et al, 1978) . Cohen et al (1980) noted that the poor palatability of guar limits its use and adds uncertainty pertaining to the degree of patient acceptance and compliance. Therefore, they conclude that it is unlikely that guar will have a useful clinical role in the treatment of diabetes. Our amylase I-V products should be more palatable than other guar gum-containing products (eg guar bread), which is essential for long-term patient compliance.
In addition, dietary supplementation with guar gum is also associated with gastrointestinal side effects (eg flatulence and diarrhea) from its colonic fermentation, because guar gum is a rapidly fermented carbohydrate (Flickinger et al, 2000) . Several experiments have noted an increased incidence of gastrointestinal side effects with guar gum supplementation (Uusitupa et al, 1989; Todd et al, 1990; Kirsten et al, 1992) even resulting in subject attrition (Cohen et al, 1980; Aro et al, 1981) . However, several studies have documented that these side effects subside after approximately 2 weeks of supplementation (Tuomilehto et al, 1980; Ebeling et al, 1988) . Todd et al (1990) suggested a gradual increase in the guar gum dose to reduce side effects and to restrict the dose to 15 g/day, which will reduce the incidence of flatulence. Other research groups have found that subjects tolerate guar gum when given at lower daily doses (o20 g/day) (Cohen et al, 1980; Carroll et al, 1981; Tuomilehto et al, 1980) . The present study was designed to test the efficacy of a low-dose guar gum-based amylase I-V system. We found that 3.6 g galactomannan supplemented to an amylase I-V system effectively blunted postprandial glycemia in healthy nondiabetic adult subjects. Amylase I-V=amylase-induced-viscosity, I-V þ fructose=amylase-induced-viscosity þ fructose. Intensity and frequency were set to a 100-mm line scale (0 representing 'absent' and 100 'severe' and 0 representing 'usual' and 100 'more than usual,' respectively). A score of 5 or less was considered not physiologically meaningful. Thus, data were classified as 0-5, 'no' and >5 'yes'. Values represent the frequency of 'yes'. n=30.
We found that 5 g supplemental fructose when fed simultaneously with an MGTT did not improve the postprandial glycemic response. These results are similar to our recent study (Heacock et al, 2002 ) in which we found that 10 g of supplemental fructose, when given with an MGTT (50 g carbohydrate from instant mashed potatoes), had no effect on the postprandial glycemic response. The lack of efficacy when fed with a meal in the present study, as compared with a free glucose beverage (Moore et al, 2000 (Moore et al, , 2001 , may be related to the effects of free glucose on the absorption of fructose (Hoekstra & van den Aker, 1996; Shi et al, 1997) . Rats have a higher capacity for absorbing free fructose compared with the human. Fujisawa et al (1991) determined that the amount of fructose that was completely absorbed by rats was 1.4-1.6 g/kg body weight, which is a 10-fold higher dose than that required to reduce the postprandial glycemic excursion in Zucker fatty fa/fa rats . This may explain why our experiments in rats showed a positive response to supplemental fructose with an MGTT.
In summary, amylase I-V provided a means to stabilize blood glucose levels by reducing the early phase excursion and also by appropriately maintaining the later phase excursion in healthy nondiabetic humans. Supplementing 5 g of fructose to a 50-g starch meal did not improve the postprandial glycemic excursion in healthy nondiabetic humans. Up to four of 30 healthy nondiabetic subjects reported a higher intensity and frequency of cramping, distension, or flatulence when they consumed the amylase I-V containing products. Amylase I-V as a component of a carbohydrate beverage did not affect the subjective ratings of hunger in healthy nondiabetic humans undergoing an MGTT
